Virtually every subspecialty in medicine in one way or another deals with angiogenesis-associated physiological or pathological processes and, without exception, every organ system in the body has many diseases in which angiogenesis is an important component. This in itself makes the study of angiogenesis mandatory, in both basic science and clinical settings. Yet the study of angiogenesis does not require this justification. As a biological process it is extraordinarily rich, touching on virtually every aspect of modern cell biology, making it almost impossible for molecular biologists, biochemists and morphologists to ignore. Considerable therapeutic benefit can now be obtained through positive or negative manipulation of the angiogenic process, and this is due in large part to the rapid transfer to the clinical setting of knowledge acquired through a cell biological approach.
Introduction
The establishment and maintenance of a vascular supply are absolute requirements for the growth of normal and neoplastic tissues and, as might be expected, the cardiovascular system is the first organ system to develop and to become functional during embryogenesis. In their simplest form as represented by capillaries, blood vessels are composed of a single layer of endothelial cells, and it has been known since the beginning of this century I that both during development and in postnatal life all vessels begin as simple endothelial-lined capillaries. Although some vessels remain as capillaries. many subsequently develop into larger vessels of greater structural complexity, a process that occurs in part through the addition of a variable number of concentrically-disposed smooth muscle cell layers. The heterogeneity and variable complexity of blood vessels thus generated serve to ensure structural and functional diversity in the vascular tree. Two interrelated but separable processes are responsible for the formation of capillary blood vessels: vasculogenesis, the differentiation in situ of mesodermal precursor cells into endothelial cells. which SUbsequently form a primary capillary plexus, and angiogenesis, the formation of new vessels by a process of sprouting from pre-existing vessels (Figure 1 ). 2.3 It is currently believed that vasculogenesis is limited to early embryogenesis. while angiogenesis occurs both during development and in postnatal life. During embryonic development, the vascular system develops at a stage when the embryo is no longer able to satisfy its nutritional requirements by diffusion alone. Vasculogenesis occurs in endodermal organ rudiments such as pancreas and lung, while bone marrow. kidney and the central nervous system are vascularized, at least in part, by an angiogenic process (Table I) . Endothelial cells are all of mesodermal origin, and observations made in the first half of this century suggested that endothelial cells arise either from angioblasts (which differentiate exclusively into endothelial cells) or from hemangioblasts (which have the dual capacity to differentiate into either endothelial or hematopoietic cellsj.t"
In postnatal life, angiogenesis plays an important role in the maintenance of functional and structural integrity of the organism (Table I) . It thus occurs in physiological processes that include the cyclical growth of capillaries within the ovary (required for ovulation and corpus luteum formation) and the endometrium (required for regeneration following menstruation), it occurs following implantation of the blastocyst and is responsible for the formation of the placenta, it is required for mammary gland development during pregnancy, and it is associated with exerciseinduced hypertrophy of skeletal muscle. In addition, angiogenesis is involved in tissue repair processes such as wound healing. bone fracture repair and recanalization of vessels occluded by intravascular thrombi; in these situations it is tightly regulated, and is limited by the metabolic demands of the issues concerned. Angiogenesis also occurs in response to tissue hypoxia, which may result from increased metabolic demand (e.g. as a consequence of exercise) or from chronic tissue hypoperfusion.
Although new collateral blood vessel formation in response to hypoperfusion may be beneficial in certain situations such as myocardial ischemia or peripheral vascular insufficiency, hypoxia-driven neovascularization may have grave consequences in certain other tissues. most notably the retina. Retinal neovascularization is a frequent complication of systemic diseases such as diabetes mellitus, and as such is one of the most common causes of blindness in our society. Excessive and inappropriate angiogenesis is the central pathogenetic mechanism underlying the formation of juvenile hemangiomas and, in this setting, the density of newly formed blood vessels far exceeds the metabolic needs of the tissue concerned. Angiogenesis is also an important constituent of the inflammatory pannus that destroys articular cartilage in rheumatoid arthritis ( Table I) .
Much of our interest in the angiogenic process comes from the notion that, for solid tumors to grow beyond a critical size, they must recruit endothelial celIs from the surrounding stroma to form their own endogenous microcirculation," since, as in the embryo, a critical stage is reached when rapidly growing tumors are no longer able to meet their nutritional requirements by diffusion alone. With respect to angiogenesis, two phases can thus be recognized in tumor progression: prevascular and vascular. The transition from the prevascular to the vascular phase is commonly referred to as the 'angiogenic switch'. The prevascular phase is characterized by an initial increase in tumor growth followed by a plateau in which the rate of tumor Vascular Medicine 1996; 1: 259-266 cell growth is balanced by an equivalent rate of cell death (apoptosis). The prevascular phase may persist for many years, and can be recognized clinically as carcinoma in situ, which is characterized by few or no metastases. During the vascular phase, which is characterized by exponential tumor growth, tissue invasion and the hematogenous spread of tumor cells, the rate of tumor cell proliferation is unaltered, and the increase in tumor growth is due largely to a decrease in the rate of tumor cell apoptosis.?" In a sense, tumor angiogenesis might almost be considered as 'appropriate', in that newly formed vessels serve to meet the metabolic demands of the rapidly growing tumor. Although this may be beneficial to the tumor itself, it is clearly detrimental to the organism, since it is permissive for continued tumor growth and also allows for the dissemination of tumor cells and the formation of metastasis.
Mechanisms of angiogenesis
During angiogenesis, new capillaries originate from preexisting capillaries or postcapillary venules. In response to an angiogenic stimulus, endothelial cells are 'activated', following which local vasodilation, increased vascular permeability and the accumulation of extravascular fibrin occur. This is followed by proteolytic degradation of the basement membrane of the parent vessel. Thin cytoplasmic processes are then extended from the activated endothelial cells, and directed migration occurs into the surrounding matrix towards the angiogenic stimulus. Migrating endothelial cells elongate and align with one another to form a capillary sprout, and endothelial cell division, which occurs proximal to the migrating tip, further increases the length of the sprout. The solid sprout gradually develops a lumen proximal to the region of proliferation. Contiguous tubular (1) Endothelial cell activation following exposure to an angiogenic stimulus is followed by basement membrane degradation and the extension of thin cytoplasmic processes in the direction of the stimulus. (2) This is followed by cell migration into the surrounding matrix and the formation of a capillary sprout. Proliferation occurs in cells proximal to the migrating front, and lumen formation begins in the region of the sprout closest to the parent vessel. (3) Sprout maturation occurs by reconstitution of the basement membrane. A functional capillary loop is formed following fusion of the tip of the sprout with a contiguous sprout. (Reproduced from ref. 13 with permission from S Karger AG, Basel.) sprouts anastomose at their tips to form a functional capillary loop in which blood flow is soon established. Vessel maturation is accomplished by reconstitution of the basement membrane.""! Together, these cellular functions contribute to the process of capillary morphogenesis, i.e. the formation of three-dimensional patent tube-like structures ( Figure 2 ). Alterations in at least three endothelial cell functions thus occur during angiogenesis: (1) interactions with the extracellular matrix, which are mediated by integral membrane proteins including integrins,'? which provide a link between the extracellular matrix and the cytoskeleton, as well as by matrix-degrading proteolytic enzymes and their inhibitors! 3; (2) an initial increase and subsequent decrease in locomotion (migration), which allows the cells to translocate towards the angiogenic stimulus and to stop once they reach their destination; (3) an increase in proliferation, which provides new cells for the growing and elongating vessel, with a subsequent return to the quiescent state once the vessel is formed.
In order to provide a functional classification for the activities of the various regulators, the multiple cell functions that occur during angiogenesis could be considered as belonging either to a phase of activation or to a phase of resolution. The phase of activation encompasses initiation and progression, and includes: (a) increased vascular permeability and extravascular fibrin deposition, (b) basement membrane degradation, (c) cell migration and extracellular matrix invasion, (d) endothelial cell proliferation and (e) capillary lumen formation. The phase of resolution encompasses termination and vessel maturation, and includes: (a) inhibition of endothelial cell proliferation, (b) cessation of cell migration, (c) basement membrane reconstitution and (d) junctional complex maturation.
It is usually stated that, with the exception of angiogenesis that occurs in response to tissue injury or in female reproductive organs, endothelial cell turnover in nonpathological settings in the adult organism is very low. The maintenance of endothelial quiescence is thought to be due to the presence of endogenous negative regulators, since positive regulators are frequently detected in adult tissues in which there is apparently no angiogenesis. The converse is also true, namely that positive and negative regulators often coexist in tissues in which endothelial cell turnover is increased. This had led to the notion that endothelial activation status is determined by a balance between positive and negative regulators: in activated (angiogenic) endothelium the positive regulators predominate, whereas endothelial quiescence is achieved and maintained by the dominance of negative regulators.i-!":"
With respect to activated endothelium, an important distinction needs to be made between physiological and pathological settings: although many of the same positive and negative regulators are operative in both, endothelial cell proliferation is tighly controlled in the former, whereas in the latter the continuous dominance of positive regulators results in unchecked endothelial cell growth. It should also be appreciated that the ultimate target for both positive and negative regulators is the endothelial cell. This has led to the notion that angiogenesis regulators may act either directly on endothelial cells, or indirectly by inducing the production of direct-acting regulators by inflammatory and other nonendothelial cells.
Among the factors that affect endothelial cell activation status, either positively or negatively, are cytokines and chemokines (chemotactic cytokines) produced by normal and tumor cells. The most thoroughly characterized of the positive regulating cytokines are vascular endothelial growth factor (VEGF) and acidic and basic fibroblast growth factors (aFGF, bFGF) ( Figure 3 ). VEGF and the FGFs are angiogenic in vivo; however, although a role for VEGF in developmental and tumor angiogenesis has been well defined, much controversy still exists as to whether or not the FGFs are relevant to the endogenous control of angiogenesis in vivo.!6-IM The finding that VEGF and FGFs are capable of positively regulating many endothelial cell functions relevant to angiogenesis in vitro, including proliferation, migration and extracellular proteolytic activity as well as the capacity of stimulated endothelial cells to invade three-dimensional extracellular matrices within which they form capillary-like tubes,19.2o has led to the notion that these factors are direct-acting positive regulators.
In contrast to VEGF and FGFs, which are mitogenic for endothelial cells, transforming growth factor 13 (TGF-13) and tumor necrosis factor alpha (TNF-a) inhibit endothelial cell growth in vitro, and have therefore been considered as direct-acting negative regulators. However, both rGF-13
and TNF-a are angiogenic in vivo, and this had led to the proposal that these cytokines induce angiogenesis indirectly by inducing the production of direct-acting positive regu--- lators from stromal and chemoattracted inflammatory cells. In this context then. TGF-J3 and TNF-a are considered to be indirect positive regulators (Figure 3 ). 16.21 Other cytokines that have been reported to regulate angiogenesis in vivo include hepatocyte growth factor (HGF). epidermal growth factor/transforming growth factor alpha (EGFITGF-a). platelet-derived growth factor-BB (pDGF-BB). interleukins (IL-l, IL-6 and IL-12). interferons. granulocyte colony stimulating factor (G-CSF). placental growth factor (PIGF). proliferin and proliferin-related protein. Chemokines that regulate angiogenesis in vivo have to date been identified only in the C-X-C family. and include IL-8. platelet factor IV. interferon-inducible protein-IO (IP-IO) and gro-B, It should also be noted that angiogenesis can be regulated by a variety of noncytokine or chemokine factors including enzymes (angiogenin, plateletderived endothelial cell growth factor (PD-ECGF)/thymidine phosphorylase); inhibitors of matrixdegrading proteolytic enzymes (matrix metalloproteinases (MMPs) and plasminogen activators (PAs)). extracellular matrix components and coagulation/fibrinolysis factors or fragments thereof (thrombospondin, tissue factor. angiostatin. hyaluronan (and oligosaccharidesj), soluble cytokine receptors. ribonuclease inhibitor. prostaglandins. adipocyte lipids and copper ions (Figure 3 ).2.16.21. 22 Although as indicated above. a large number of polypep-Vascular Medicine 1996; 1: 259-266 tide and nonpolypeptide molecules have been shown to regulate angiogenesis in the experimental setting ( Figure 3 ). it is crucial to bear in mind that modulation of angiogenesis through exogenous application of putative positive or negative factors does not necessarily imply that these factors are endogenous regulators. i.e. that they are relevant to the control of angiogenesis in the intact organism. In the case of molecules that are active during the phase of activation only one. namely VEGF. meets most of the criteria required for the definition of an 'angiogenic factor' . 16.23 Furthermore. it has long been proposed that angiogenesis is driven by tissue hypoxia in both prenatal and postnatal life. and it has now been conclusively demonstrated that hypoxia is a major positive regulator of VEGF synthesis.P'>" In contrast to the phase of activation. very little is known about the factors involved in the phase of resolution. in which the dominant activity of negative regulators is called into play. Furthermore. it is at present unclear as to whether the resolution phase is an active phase. or whether it is the consequence of exhaustion of positive regulators that had predominated during the phase of activation. If the latter hypothesis is correct. this would assume that endothelial cells have the inherent capacity to synthesize their own basement membrane and to organize into capillary-like tubes. and that this is mediated in part by the autocrine activity of endogenous regulators.
From cell biology to the clinic
Based on a large body of experimental evidence, it is currently believed that considerable benefit can be derived in the clinical setting from manipulating angiogenesis, either positively or negatively. Table 2 provides a nonexhaustive list of those situations likely to benefit from stimulation of angiogenesis (sometimes referred to as 'therapeutic angiogenesis') or inhibition of angiogenesis (antiangiogenesis).
Therapeutic stimulation of angiogenesis
Stimulation of angiogenesis is expected be of benefit in wound healing and fracture repair, and the notion that therapeutic angiogenesis may be beneficial in the treatment of ischemla'":" has recently received considerable support. Two settings that may benefit from this form of therapy (which is sometimes referred to as 'molecular bypass grafting') are coronary artery disease and peripheral arterial occlusive disease. In both of these settings, the objective is to reduce tissue hypoxia in areas of hypovascularization by local stimulation of angiogenesis. It should be pointed out that the creation of new vascular channels may be the result either of angiogenesis itself or of the recruitment (through vasodilatation) of existing vascular channels.
With respect to the heart, local application of exogenous growth factors for the treatment of myocardial ischemia has bee? investigated in a number of animal models. Angiogenre factors that have been assessed in these models include bFGF and VEGF. In all of these studies a significant beneficial effect was documented, including reduction in infarct size, improved systolic function, increased coronary blood flow and an increase in vessel density as demonstrated by histology.P:" All of these studies entailed application of the angiogenic factor itself. However, one recent study has demonstrated the efficacy of a gene therapy approach in a porcine model of ameroid constrictor-induced myocardial ischemia. In this study, intracoronary application of recombinant adenovirus expressing human FGF-5 (which unlike bFGF contains a signal peptide and is therefore likely to enter the classical secretory pathway) resulted in marked improvement in myocardial function and blood flow as well as an increase in capillary density."?
The use of angiogenic factors to increase blood flow to ischemic myocardium is a concept that is currently undergoing preliminary testing in several clinical trials."
With respect to the periphery, the beneficial effect of therapeutic angiogenesis in the induction of collateral formation has been clearly demonstrated in animal models of hindlimb ischemia; bFGF, VEGF and PDGF-BB have been used successfully in these models, and have been administered by intramuscular injection or as a single intra-arterial bolus dose proximal to a femoral artery ligation."?" A recent study'" has demonstrated that combined administration of bFGF and VEGF in a rabbit model of hindlimb ischemia induces an increase in collateral formation that is far superior to the effect seen with either cytokine alone.
These in vivo studies confirm earlier in vitro findings on synergism between bFGF and VEGF,2ll and point to the potentially important therapeutic applications of this observation. Finally, the use of a gene transfer approach with VEGF to increase blood flow to ischemic muscle in the lower limb is currently undergoing preliminary testing in clinical trials. 5 1.52 Other settings that may benefit from therapeutic angiogenesis include improvement of survival of free or pedicled skin flaps53- 55 and organ transplantation including transplantation of islets of Langerhans. With respect to the central nervous system, it has been shown that intraventricular or intracortical application of bFGF promotes angiogenesis (increase in vessel density) and prevents neuronal degeneration in models of chronic cerebral ischemia in rats and gerbils.t'"?" However, it remains to be determined whether the ability of bFGF to prevent neuronal degeneration is the consequence of neovascularization or of a direct trophic effect on neuronal and nonneuronal elements.
Inhibition of angiogenesis
Foremost amongst the settings in which the notion of antiangiogenesis has been promoted is the inhibition of solid tumor growth and the spread of metastasis. In his classic article on tumor angiogenesis in 1974, Folkman". highlighted a number of points in the angiogenic process that might be targets for anti-angiogenesis therapy. These included: '( I) interruption of tumor-angiogenesis factor (TAF) synthesis; (2) blockade of transmission of TAF through tissues; (3) prevention of endothelial cell mitosis; (4) prevention of vessels from penetrating tumor.' These and other events that constitute the activation and resolution phases of angiogenesis have indeed proven to be appropriate targets for a variety of anti-angiogenic agents." Furthermore, anti-angiogenic therapies directed at angiogenic factors and their receptors, endothelial cell proliferation and migration, and extracellular matrix synthesis and degradation, have proven to be highly effective in a variety of other settings in which angiogenesis is a prominent component of the disease.
A large amount of descriptive data has clearly pointed to the importance of VEGF and its cognate receptors in tumor angiogenesis.f These observations have led to the development of strategies aimed at inhibiting tumor growth by interfering with cytokine-receptor interactions. These include anti-V~GF antibodies, soluble VEGF receptors (VEG~s), antl-s~nse VEGF, a VEGF-toxin conjugate and a dominant negative approach using a truncated form of V~GFR_2.63-71~in~e VEGF is an endothelial-specific mitogen, these findings unambiguously demonstrate the essential requirement for angiogenesis in tumor growth. In addition to VEGFNEGFR antagonists, a large number of polypeptide and nonpolypeptide inhibitors have been successfully used for the inhibition of tumor angiogenesis. Some of these are potential endogenous inhibitors (i.e. they may be involved in the physiological regulation of angiogenesis) and include inhibitors of matrix-degrading proteases (tissue inhibitors of metalloproteinases (TIMPs) and PA inhibitors), interferons, thrombospondin, platelet factor 4, a 16 kDa fragment of prolactin, IP-lO, gro-B, IL-12, angiostatin (an internal fragment of plasminogen) and certain steroids and their metabolites (Figure 3 ). Other inhibitors include AGM-1470ffNP-470 (a fumagillin derivative) and other angiostatic antibiotics, synthetic metalloproteinase inhibitors, angiostatic polysaccharides, suramin analogues, integrin (particularly a v l33) antagonists, genistein (a tyrosine kinase inhibitor) and thalidomide.':"
Other situations in which anti-angiogenesis therapy has been successful include juvenile hemangioma, experimental inflammatory arthritis, and proliferative retinopathy (in which interferon alpha and thalidomide are currently being tested in clinical trials)." The proven efficacy of interferon alpha-2a (IPN-a2a) in juvenile hemangiomas may be related to experimental evidence suggesting that it inhibits angiogenesis.Fr" either by interacting directly with endothelial cells" or by reducing angiogenic factor production by stromal cells." Although inhibitors of angiogenesis have not been studied in clinical trials in patients with rheumatoid arthritis, it is likely that TIMPs (possibly via a gene therapy approach) as well as other matrix metalloproteinase inhibitors will prove to be efficacious owing to their combined anti-angiogenic and chondroprotective effects.
Finally, since angiogenesis is prominent in the ovary and uterus during specific phases of the female hormonal cycle, and since angiogenesis is critical for early postimplantation development and formation of the placenta, the concept of anti-angiogenesis in the context of birth control certainly merits investigation. Furthermore, it is possible that certain forms of infertility may be associated with aberrant angiogenesis.
Conclusion
Stimulation or inhibition of angiogenesis has proved to be extremely successful in animal models of a wide variety of diseases, and appears to be meeting with a certain degree of success in the early phases of clinical trials in humans as an adjunct to established/conventional forms of therapy. However, prospects in the short term look slightly better for therapeutic angiogenesis than for anti-angiogenesis. Thus, in contrast to anti-angiogenesis therapy, which is likely to require long-term (possibly lifelong) administration of inhibitory agents, therapeutic angiogenesis is likely to necessitate only brief periods of treatment. Both nonspecific and specific side-effects of anti-angiogenesis therapy, including those related to inhibition of physiological angiogenesis, are therefore likely to pose more of a problem than are the side-effects seen with stimulation of angiogenesis. It is interesting to note that high circulating levels of angiogenic factors such as VEGF and bFGF, as seen for example in patients with a variety of tumors.?"?" do not appear to promote a generalized or systemic angio-Vascular Medicine 1996; I: 259-266 genic state. Similarly, no overt side-effects associated with uncontrolled nonspecific angiogenesis have been reported in animal models of ischemia requiring long-term administration of angiogenic factors." or in transgenic mice that systemically overexpress human bFGF in a constitutive manner." On the other hand, long-term use of IPN-a2a in children with complicated hemangiomas may result in the development of spastic diplegia," a heretofore unpredictable side-effect, and it is likely that many other anti-angiogenic agents will have both predictable and unpredictable toxicity profiles. There is no doubt however that, in the long term, when used in conjunction with other treatment modalities, anti-angiogenesis is likely to have as much of an impact in patients with chronic diseases including cancer as will therapeutic angiogenesis in patients with ischemia.
